Found 26 matching trials
Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)
PHASE1The purpose of this study is to evaluate the pharmacokinetics (PK), safety,...
Location
Local Institution
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
PHASE2This phase II trial studies how well brivanib alaninate works in treating p...
Location
Saint Joseph's Hospital and Medical Center
First Line Hepato Cellular Carcinoma (HCC)
PHASE3The purpose of this study is to compare the overall survival of brivanib ve...
Location
Mayo Clinic Arizona
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
PHASE2The purpose of this study is to determine if gastric/esophageal, lung, panc...
Location
University Of Chicago
A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)
PHASE1The purpose of this trial is to determine the effect of food versus a faste...
Location
Dana-Farber Harvard Cancer Care
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
PHASE2The purpose of this clinical research study is to learn if BMS-582664 can s...
Location
City Of Hope National Medical Center
A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
PHASE1The purpose of this study is to assess the dose limiting toxicity (DLT) of ...
Location
Local Institution
Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF
PHASE2The goal of this clinical research study is to learn if adding brivanib to ...
Location
UT MD Anderson Cancer Center
A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC
PHASE2This is a Phase 2, Open-label, Randomized, Multicenter Study to Investigate...
Location
Anhui Provincial Hospital
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
PHASE3The purpose of this study is to compare the Overall Survival (OS) of HCC pa...
Location
Richard Finn, M.D.